Keros Therapeutics (NASDAQ:KROS) Now Covered by Oppenheimer

Analysts at Oppenheimer assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a note issued to investors on Tuesday, Marketbeat.com reports. The firm set an “outperform” rating and a $102.00 price target on the stock. Oppenheimer’s target price would indicate a potential upside of 119.45% from the stock’s current price.

A number of other equities analysts have also recently commented on KROS. Wedbush restated an “outperform” rating and set a $86.00 target price on shares of Keros Therapeutics in a report on Thursday, February 29th. Truist Financial restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Piper Sandler restated an “overweight” rating and set a $105.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 27th. Finally, HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $88.29.

Keros Therapeutics Trading Up 0.1 %

NASDAQ KROS opened at $46.48 on Tuesday. The stock has a market cap of $1.68 billion, a PE ratio of -9.03 and a beta of 1.25. Keros Therapeutics has a twelve month low of $27.02 and a twelve month high of $73.00. The stock has a fifty day simple moving average of $52.22 and a 200-day simple moving average of $54.20.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.12. The business had revenue of $0.08 million for the quarter. The company’s revenue for the quarter was down 97.3% on a year-over-year basis. During the same period in the previous year, the company posted ($1.26) EPS. Research analysts predict that Keros Therapeutics will post -4.98 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Keros Therapeutics by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock worth $102,329,000 after acquiring an additional 113,563 shares in the last quarter. Darwin Global Management Ltd. raised its position in shares of Keros Therapeutics by 35.4% during the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock worth $95,060,000 after acquiring an additional 375,523 shares in the last quarter. Braidwell LP raised its position in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Braidwell LP now owns 1,357,309 shares of the company’s stock worth $43,271,000 after acquiring an additional 213,444 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Keros Therapeutics by 17.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after acquiring an additional 176,803 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Keros Therapeutics by 47.9% during the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after acquiring an additional 226,674 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.